Journey Medical Corp <DERM.OQ> expected to post a loss of 10 cents a share - Earnings Preview
Journey Medical Corp DERM.OQ DERM.O is expected to show a rise in quarterly revenue when it reports results on August 12 for the period ending June 30 2025
The Scottsdale Arizona-based company is expected to report a 0.5% increase in revenue to $14.933 million from $14.86 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Journey Medical Corp is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Journey Medical Corp is $10.00, about 24.3% above its last closing price of $7.57
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.23 | -0.24 | -0.18 | Beat | 24.2 |
Dec. 31 2025 | -0.35 | -0.15 | Beat | 57.4 | |
Sep. 30 2024 | -0.14 | -0.15 | -0.17 | Missed | -15.3 |
Jun. 30 2024 | -0.14 | -0.14 | -0.17 | Missed | -18.6 |
Mar. 31 2024 | -0.23 | -0.23 | -0.53 | Missed | -125.5 |
Dec. 31 2023 | -0.09 | -0.08 | -0.12 | Missed | -56.5 |
Sep. 30 2023 | -0.11 | -0.15 | 0.80 | Beat | 616.1 |
Jun. 30 2023 | -0.35 | -0.33 | -0.29 | Beat | 13.4 |
This summary was machine generated August 9 at 00:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
